Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesShuttle Pharmaceuticals Inc

Shuttle Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
5.25 USD -0.09 ( 1.69%)
Last update at 2026-11-11T21:00:00Z
VOLUME
12830
Market Cap
7.45M

Momentum Score

…

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.08
Low
5.44
High
52 Week Price Range
0.35
Low
1.27
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly listed Shuttle Pharmaceuticals Inc. has limited publicly available information about its operations and product pipeline, and company disclosures are sparse. It appears positioned as a development-stage biopharmaceutical company where long-term growth drivers would include clinical trial progress, regulatory milestones, partnership or licensing deals and successful commercialization, which may benefit shareholders if programs advance.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.34
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.27
ROE
-152.02%
Net Debt
-1.49M
ROCE
-52.03%
Diluted EPS TTM
-0.50

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2018-12-31 2016-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2018-12-31 2016-12-31
Income before tax -3.03M -1.15M -0.81M - -
Net income -3.10M -1.20M -0.85M - -
Selling general administrative 1.07M 0.72M 0.35M - -
Reconciled depreciation 0.07M 0.02M 0.02M - -
Ebit -2.55M -1.74M -0.51M -0.59M -0.34M
Ebitda -2.16M -1.68M -0.45M - -
Depreciation and amortization 0.40M 0.06M 0.05M - -
Operating income -2.55M -1.74M -0.51M - -
Other operating expenses 2.55M 1.74M 0.51M - -
Interest expense 0.97M 0.05M 0.04M - 0.00M
Tax provision 0.00M 0.00M 0.00M - -
Net interest income -0.97M -0.05M -0.04M - -
Income tax expense 0.07M 0.05M 0.04M - -
Total revenue 0.00M 0.00M 0.00M - -
Total operating expenses 2.55M 1.74M 0.51M - -
Total other income expense net -0.47M 0.59M -0.30M - -
Net income from continuing ops -3.03M -1.15M -0.81M - -
Net income applicable to common shares -3.10M -1.26M -0.91M -0.63M -0.34M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2018-12-31
Total assets 5.95M 8.65M 0.65M 0.54M -
Other current assets 0.11M 0.16M 0.00M 0.01M 0.25M
Total liab 1.90M 0.98M 2.28M 2.23M -
Total stockholder equity 4.06M 7.68M -1.63M -1.69M -
Other current liab 0.11M 0.11M 0.09M 0.67M 0.02M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.02M 0.02M -
Retained earnings -15.49M -8.89M -5.80M -4.54M -1.91M
Other assets - 0.01M 0.01M 0.01M 0.01M
Cash 2.58M 8.42M 0.50M 0.12M -
Total current liabilities 1.04M 0.98M 2.22M 2.10M 0.59M
Current deferred revenue - - 0.38M 0.23M -
Net debt -1.49M -7.67M 0.47M 0.70M -
Short term debt 0.65M 0.75M 0.92M 0.69M -
Short long term debt 0.60M 0.69M 0.85M 0.63M -
Short long term debt total 1.09M 0.75M 0.98M 0.82M -
Other stockholder equity 19.54M 16.57M 4.17M 2.85M 0.02M
Property plant equipment - 0.07M 0.14M 0.20M 0.00M
Total current assets 5.59M 8.58M 0.51M 0.34M 0.61M
Net tangible assets - 7.68M -1.63M -1.69M 0.03M
Short term investments 2.89M - - - -
Net receivables 0.01M - 0.00M 0.21M 0.00M
Long term debt 0.14M - - - -
Accounts payable 0.28M 0.12M 0.83M 0.52M 0.03M
Non currrent assets other - 0.01M 0.01M 0.01M -
Non current assets total 0.36M 0.08M 0.14M 0.20M -
Capital lease obligations 0.36M 0.06M 0.13M 0.19M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2018-12-31 2016-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2018-12-31 2016-12-31
Investments - 0.00M -0.01M - -
Change to liabilities -0.38M 0.31M -0.05M -0.05M 0.00M
Total cashflows from investing activities - - -0.01M -0.01M 0.02M
Net borrowings 0.60M 0.69M 0.07M 0.21M 0.15M
Total cash from financing activities 10.62M 0.69M 0.07M 0.87M 0.17M
Change to operating activities -0.17M -0.00M -0.11M 0.02M 0.06M
Net income -3.03M -1.15M -0.81M -0.63M -0.34M
Change in cash 7.91M 0.39M 0.03M 0.30M -0.04M
Begin period cash flow 0.50M 0.12M 0.08M 0.12M -
End period cash flow 8.42M 0.50M 0.12M 0.08M 0.12M
Total cash from operating activities -2.71M -0.30M -0.03M -0.57M -0.23M
Issuance of capital stock 10.02M - - - -
Depreciation 0.07M 0.06M 0.05M 0.02M 0.02M
Other cashflows from investing activities - - - - 0.02M
Dividends paid -0.40M - - - -
Change to account receivables 0.00M 0.21M 0.16M 0.05M 0.03M
Other cashflows from financing activities 1.05M 0.69M -0.01M -0.25M -
Change to netincome -0.08M 0.27M 0.72M 0.02M 0.00M
Capital expenditures 0.00M 0.00M 0.01M 0.01M 0.00M
Change in working capital -0.56M 0.52M 0.01M - -
Stock based compensation 0.40M 0.91M 0.46M - -
Other non cash items 0.40M 0.00M 0.26M - -
Free cash flow -2.71M -0.30M -0.04M - -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
SHPH
Shuttle Pharmaceuticals Inc		 -0.09
1.69%		 5.25 - - - 1.70 -0.62
MKKGY
Merck KGaA ADR		 0.13
0.39%		 33.80 21.25 14.93 3.10 2.14 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 169.12 24.86 15.11 3.13 1.98 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.84 - 10.96 0.01 1.20 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 23.11

Profile*

Shuttle Pharmaceuticals Inc

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

One Research Court, Rockville, MD, United States, 20850

240 403 4212

https://www.shuttlepharma.com

8

Name Title Year Born
Dr. Anatoly Dritschilo M.D. Co-Founder, MD, CEO & Chairman 1944
Mr. Peter Dale Dritschilo M.B.A., M.D. Pres & COO 1969
Mr. Michael P. Vander Hoek CFO and VP of Operations & Regulatory 1960
Dr. Milton Brown CSC, M.D., Ph.D. Co-Founder, Chief Scientific Officer for Chemistry & Director 1965
Dr. Mira Jung Ph.D. Co-Founder & Chief Scientific Officer for Biology 1949
Mr. Gene Jung Esq. Gen. Counsel NA
Dr. Tyvin A. Rich M.D. Chief Clinical Officer 1949
Dr. Theodore L. Phillips M.D., Ph.D. Clinical Director 1933
Mr. Michael Jeffrey Starkweather VP of Bus. Devel. 1984
Mr. Peter Dale Dritschilo M.B.A., M.D. President & COO 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…